Date:10/29/2010

ments (1.0) - (1.0) - Purchases of property, plant and equipment (53.5) (67.5) (261.7) (169.4) Purchases of intangible assets - (1.0) (2.7) (7.0) Proceeds from disposal of non-current investments and property plant and equipment - - 2.1 19.7 Proceeds from disposal of subsidiary undertakings - - - 6.7 Returns of equity investments - - - 0.2 Net cash used in investing activities(B) (628.7) (71.9) (831.5) (235.4) CASH FLOWS FROM FINANCING ACTIVITIES: Payment under building financing obligation (0.4) (0.9) (1.8) (3.9) Extinguishment of building finance obligation - - (43.1) - Tax benefit of stock based compensation 5.2 - 9.6 - Proceeds from exercise of options 0.2 1.8 2.1 2.8 Payment of dividend - - (49.8) (43.0) Payments to acquire shares by Employee Share Ownership Trust ("ESOT") - - (1.7) (1.0) Net cash provided by/(used in) financing activities(C) 5.0 0.9 (84.7) (45.1) Effect of foreign exchange rate changes on cash and cash equivalents (D) (7.5) 6.4 (1.4) 5.0 Net (decrease)/increase in cash and cash equivalents(A) +(B) +(C) +(D) (489.2) 69.4 (305.6) 114.5 Cash and cash equivalents at beginning of period 682.5 263.3 498.9 218.2 Cash and cash equivalents at end of period 193.3 332.7 193.3 332.7

Unaudited US GAAP results for the three months and nine months to September 30, 2010

Selected Notes to the Financial Statements (1) Earnings per share 9 months 9 months 3 months to 3 months to to to September September September 30, September 30, 30, 30, 2010 2009 2010 2009 $M $M $M $M Income from continuing operations 96.3 59.6 422.7 329.5 Loss from discontinued operations - - - (12.4) Noncontrolling interest in subsidiaries - - - 0.2 Numerator for basic EPS 96.3 59.6 422.7 317.3 Interest on convertible bonds, net of tax (1) - - 25.2 - Numerator for diluted EPS 96.3 59.6 447.9 317.3 Weighted average number of shares: Millions Millions Millions Millions Basic(2) 547.0 540.6 546.1 540.0 Effect of dilutive shares: Stock options(3) 9.7 7.7 10.4 7.1 Convertible
'/>"/>

SOURCE Shire plc Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related biology technology :

1. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
2. Reportlinker Adds Shire plc: PharmaVitae Profile
3. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
4. Shire plc - Statement re ProAmatine
5. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
6. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
7. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
8. Shire plc Appoints Two New Board Directors
9. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
10. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
11. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.